Impeding the adaptive response of prostate cancer to androgen targeted therapies with relaxin receptor antagonist
2015
Androgen deprivation and
androgen targeted therapies (ATT) are
established treatments for prostate cancer
(PCa). Although initially effective, ATT
induces an adaptive response that leads to
treatment resistance. Increased expression
of relaxin-2 (RLN2) is an important alteration
in the adaptive response. RLN2 has a
well described role in PCa cell proliferation,
adhesion and tumour growth. The objectives
of this study were to develop cell models
for studies of RLN2 signalling and to
implement in vitro assays for evaluating the
therapeutic properties of the unique RLN2
receptor (RXFP1) antagonist
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI